A new mid-size molecule drug for the treatment of schizophrenia targeting at the VPAC2 receptor

○Yukio Ago

[2Pa-115] A new mid-size molecule drug for the treatment of schizophrenia targeting at the VPAC2 receptor

○Yukio Ago¹, Kotaro Sakamoto², Satoshi Asano¹ (1. Dept Cell Mol Pharmacol, Grad Sch Biomed Health Sci, Hiroshima Univ, Hiroshima, Japan, 2. Ichimaru Pharcos Co Ltd, Gifu, Japan)

Keywords:Schizophrenia, VIPR2 (VPAC2 receptor), Antagonist, Bicyclic peptide

Abstract password authentication.
A password is required to view the full text of the abstract. Please refer to the member site for the password.

https://membership.jnss.org/C00/login

Presentation information

[2Pa] Schizophrenia

[2Pa-115] A new mid-size molecule drug for the treatment of schizophrenia targeting at the VPAC2 receptor

Password